ausblenden:
Schlagwörter:
Extracellular matrix (ECM); Chemotherapy; Chemoresistance; Metastasis; Tumor microenvironment; Ligands
Zusammenfassung:
The general progression of cancer drug development involves in vitro testing followed by safety and efficacy evaluation
in clinical trials. Due to the expense of bringing candidate drugs to trials, in vitro models of cancer cells and
tumor biology are required to screen drugs. There are many examples of drugs exhibiting cytotoxic behavior in
cancer cells in vitro but losing efficacy in vivo, and in many cases, this is the result of poorly understood
chemoresistant effects conferred by the cancer microenvironment. To address this, improvedmethods for culturing
cancer cells in biomimetic scaffolds have been developed; along theway, a great deal about the nature of cancer
cell-extracellular matrix (ECM) interactions has been discovered. These discoveries will continue to be
leveraged both in the development of novel drugs targeting these interactions and in the fabrication of biomimetic
substrates for efficient cancer drug screening in vitro.
